Caricamento...
Interferon-β treatment for multiple sclerosis
Multiple sclerosis (MS) is the leading nontraumatic cause of neurologic disability in young adults. Interferon-β, approved for use in 1993, was the first treatment to modify the course and prognosis of the disease and remains a mainstay of MS treatment. Numerous large-scale clinical trials in early,...
Salvato in:
| Pubblicato in: | Neurotherapeutics |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer-Verlag
2007
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7479675/ https://ncbi.nlm.nih.gov/pubmed/17920544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nurt.2007.07.001 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|